Understanding monogenic causes of cardiomyopathies uncovers critical molecular pathways of remodeling, defining novel therapeutic targets for genetic and acquired heart failure.
May guide targeted therapies in genetic cardiomyopathies; leaves open translation to acquired heart failure.
Factors that render patients with cardiovascular disease at high risk for heart failure remain incompletely defined. Recent insights into molecular genetic causes of myocardial diseases have highlighted the importance of single-gene defects in the pathogenesis of heart failure. Through analyses of the mechanisms by which a mutation selectively perturbs one component of cardiac physiology and triggers cell and molecular responses, studies of human gene mutations provide a window into the complex processes of cardiac remodeling and heart failure. Knowledge gleaned from these studies shows promise for defining novel therapeutic targets for genetic and acquired causes of heart failure.
No takes yet. Share an insight, caveat, or question.
Morita et al. (2005) conducted a review in Heart failure and cardiomyopathies. Single-gene mutations was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: